Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

GPhC Council allows continuation of remote hearings

The pharmacy regulator can hold hearings and meetings either remotely or in-person in future as the Council of the GPhC has agreed to a change in its rules.

The rules are expected to come into force on 1 October 2022. Until the rules and new policy and guidance come into force, the GPhC will continue to only hold remote hearings with the consent of the person concerned and/or their legal representative.


Following positive feedback from those taking part in remote hearings, the GPhC consulted on a proposed permanent change to its rules so it could continue to hold hearings remotely in the future, when it is fair and appropriate to do so.

The proposal to continue remote hearings, including fitness to practice hearings, received wide support with 78 per cent of respondents agreeing.

“During the COVID-19 pandemic lockdown and restrictions we had to hold many meetings and hearings remotely by videolink. As such we were granted – along with other regulators – a temporary provision to enable us to do this and carry out our statutory role,” Duncan Rudkin, chief executive of the GPHC, said.

“We found people responded well to remote hearings. For example, registrants seemed more likely to attend a remote hearing than an in-person one. Feedback from those taking part was also mostly positive and supported the idea of remote hearings in the future. Our consultation has also highlighted potential benefits of remote hearings for people, including people sharing protected characteristics such as disability and pregnancy.

Many responses highlighted the effectiveness of remote hearings in terms of travelling time and costs incurred by registrants and the GPhC itself. Remote hearings were also seen as more efficient, enabling cases to be listed and therefore resolved quicker.

Another advantage some highlighted was that remote hearings could be more flexible for participants in terms of scheduling dates and times to attend and more accessible for people with disabilities and other accessibility needs.

The main disadvantage cited by those who were not supportive of continuing remote hearings was the risk of technological problems with remote hearings, including poor Wi-Fi connection. Responses also cited the loss of non-verbal communication such as body language, compared to in-person hearings.

The Council agreed at the meeting to make the changes to the rules. The Council also committed to a review of our existing guidance on remote hearings in the light of the consultation analysis with a view to bringing a further report to Council to agree a Policy and Guidance document on Remote Hearings in September 2022.

The updated rules will now go to the Privy Council for approval before being laid in the Westminster and Scottish Parliaments.

More For You

Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
23andMe

More than 150,000 UK residents had their personal information taken by hackers during a data breach in 2023.

iStock

UK watchdog fines 23andMe £2.31m for data breach

Genetic testing firm 23andMe has been fined £2.31 million by a UK watchdog over a 2023 data breach, when the personal information of seven million people across the world was stolen.

The Information Commissioner's Office (ICO) said the California-based company, which later filed for bankruptcy, failed to put adequate measures in place to secure sensitive user data.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less